
Pre-made Lumiliximab benchmark antibody ( Whole mAb, anti-FCER2/CD23 therapeutic antibody, Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-327
Pre-Made Lumiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-327-1mg | 1mg | 3090 | ||
GMP-Bios-ab-327-10mg | 10mg | 21890 | ||
GMP-Bios-ab-327-100mg | 100mg | 148000 | ||
GMP-Bios-ab-327-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Lumiliximab biosimilar, Whole mAb, Anti-FCER2/CD23 Antibody: Anti-BLAST-2A/CLEC4J/FCE2/FCErII/IGEBF therapeutic antibody |
INN Name | Lumiliximab |
Target | CD23 |
Format | Whole mAb |
Derivation | Chimeric (Mouse/Human) |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Discontinued |
100% SI Structure | None |
99% SI Structure | 3fzu:HL:CD |
95-98% SI Structure | None |
Year Proposed | 2004 |
Year Recommended | 2004 |
Companies | Biogen Idec |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
